Drugs / BRII-297
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05845840 | May → Nov 2023 | postpartum depression | Brii Biosciences Limited | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-01 | Brii Biosciences Limited | Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders briibio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRII-297 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05845840 ↗ |
| Route | Intramuscular | “Participants will receive a BRII-297 by Intramuscular injection” NCT05845840 ↗ |